Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 9/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729834 | 0.91 | ALDH1A1 (0.39) | GRIN2BMGLLSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL22729652 | 0.91 | MGLL (0.39) | MGLLDRD2DRD3KCNH2 | |
| SCHEMBL29839347 | 0.91 | MGLL (0.39) | MGLLDRD2DRD3KCNH2 | |
| SCHEMBL29839364 | 0.90 | MGLL (0.40) | GRIN2BMGLLKDM4EALOX15MAPK1 | |
| SCHEMBL22729707 | 0.90 | MGLL (0.40) | MGLLSLC6A4SLC6A2SLC6A3KDM4E | |
| SCHEMBL22729492 | 0.90 | MGLL (0.40) | GRIN2BMGLLKDM4EALOX15MAPK1 | |
| SCHEMBL23116381 | 0.89 | MGLL (0.39) | MGLLALOX15MAPK1DRD2DRD3 | |
| SCHEMBL23116409 | 0.89 | MGLL (0.39) | MGLLKDM4EALOX15MAPK1DRD2 | |
| SCHEMBL29839276 | 0.89 | MGLL (0.39) | MGLLALOX15MAPK1DRD2DRD3 | |
| SCHEMBL22729863 | 0.87 | SLC6A2 (0.37) | MGLLSLC6A4SLC6A2SLC6A3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | GRIN2B 1405/4885MGLL 92/4885SLC6A4 2998/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | GRIN2B 1390/4885MGLL 91/4885SLC6A4 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.